Skip to content
Monday, November 16, 2026
Lumen Enterprise

Giving Pluripotent Cells in Utero to Infants with Spina Bifida Enhances Quality of Life, Research Shows

A groundbreaking clinical study has found that delivering regenerative cells to developing infants affected by spina bifida as part of a surgical repair could constitute a "major milestone" in addressing congenital conditions.

Study Parameters and Security

The US-based trial involved six developing infants with the 'open' form of spina bifida. Surgeons applied placenta-derived mesenchymal stem cells directly onto the baby's spinal cord while the defect was being closed.

Significantly, the cell therapy proved to be secure. Researchers confirmed that the cells did not cause tumors, hinder surgical recovery, or impede the resolution of co-occurring hindbrain herniation.

Encouraging Results

Post-birth MRI scans showed a complete reversal of brainstem displacement in each of the babies. This brain structure normalization is closely linked to better mobility and function.

"Should it enable a greater number of infants to achieve ambulation who otherwise would not, then it would become their standard of care," noted the study director. "These findings are super exciting and create a pathway toward a variety of prospective novel therapies."

Broader Impact and Encouragement

Commentators reviewing the findings proposed that further confirmation of these noted improvements could herald a "new era" in fetal surgery. The prospect of enhancing neural deficits present before birth is regarded as a paradigm-shifting aim.

Particularly welcome would be advancements for continence and digestive health, which are frequent complications for those diagnosed with this condition.

The Path Forward

While this initial trial was small in scale, its safety demonstration and positive signals offer a robust platform for broader investigative efforts. The addition of cellular treatment with established fetal surgery techniques offers substantial hope for transforming outcomes for babies yet to be born with myelomeningocele.

DG
Written by

Donna Green

A UK-based business strategist with over 15 years of experience in enterprise technology and digital transformation.

Lumen Enterprise

Type to search articles.